MedTrace Logo

Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese Participants

NCT07765160 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2026-08-14

No results posted yet for this study

Summary

Clinical trials of IBI3040 with single-dose administration in healthy participants and multiple-dose administration in overweight or obese participants.

Conditions

  • Healthy Participants
  • Overweight or Obese Participants

Interventions

DRUG

SAD: subcutaneous injection in the abdomen

SAD: Single subcutaneous administration, with a safe follow-up period of 60 days

DRUG

MAD: subcutaneous injection in the abdomen

MAD: Multiple administration, subcutaneous injection

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-30
Primary Completion
2027-11-10
Completion
2027-12-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07765160 on ClinicalTrials.gov